Denmark
Bactolife, a Danish biotech firm founded in 2017, is dedicated to enhancing global health through scientific food ingredients, with a particular focus on the gut microbiome. Their innovative product, the Binding Proteins, offers a groundbreaking solution in gut health by selectively binding and blocking harmful microbial activity, thus preserving the beneficial microbiome.
Bactolife's Binding Proteins are versatile enough to be used in a variety of consumables such as foods, beverages, and supplements, catering to a diverse range of needs from children to the elderly, including immune-compromised individuals and animals. This innovation is essential not only for promoting health but also in supporting the fight against antimicrobial resistance.
The firm has attracted significant investment, most recently securing a €30.00M Series A investment on 08 August 2023, supported by prominent entities such as Novo Holdings, the Bill & Melinda Gates Foundation, European Equity Partners, and ATHOS. With a competitive pricing strategy, Bactolife aims to make their Binding Proteins a staple in diets worldwide, reinforcing their commitment to improving global gut health.
